SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP

摘要

Provided herein is a combination product comprising a Bcl-2inhibitor, an anti-CD20 antibody and/or bendamustine or a combinationproduct comprising a Bcl-2 inhibitor and CHOP, the combination productprovides a use of the combination product for prevention and/or treatmentof a disease (e.g. , cancer, rheumatoid arthritis (RA), granulomatosis withpolyangiitis (GPA), and microscopic polyangiitis).